Clinical trials: Borderline Ovarian Tumor
Ovarian Cancer, Ovarian Tumor
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
The goal of this observational study is to learn if a computer program can tell what type of ovarian tumour a person has from a CT scan taken before surgery. The program uses artificial intelligence (AI).
- Conditions
- Ovarian Cancer, Ovarian Tumor, Borderline Ovarian Tumor
- Trial name
- OvaClass (NCT07883551)
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as…
- Conditions
- Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT01081262
- Testing
- Bevacizumab, Capecitabine, Carboplatin
- Where
- 248 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade…
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
- Trial name
- NCT02101788
- Testing
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
- Where
- 501 sites in United States, United Kingdom
- Volunteers
- 260 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Ovarian Cancer, Borderline Ovarian Tumors
A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer
The study aims to improve the diagnosis of ovarian cancer by distinguishing between borderline ovarian tumors (BOT) and stage I invasive ovarian cancer.
- Trial name
- BIOC (NCT06709872)
- Where
- 4 sites in Belgium, Czechia and 1 more
- Volunteers
- 400 people
- Sponsor
- KU Leuven
Ovarian Neoplasm Epithelial Borderline
Distress, Anxiety and Psychosexual Health in BOT
The aim of this study is to assess the prevalence of distress, anxiety and psychosexual anguish in patients diagnosed with borderline ovarian tumor (BOT) compared to controls confronted with surgical treatment for benign ovarian…
- Trial name
- NCT04253327
- Testing
- questionnaire
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Universitair Ziekenhuis Brussel
Ovarian Cancer, Ovarian Cyst Benign
Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin
OVAmiARN is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in 8 obstetrics and gynecology departments in France; in order to describe the evolution of salivary miRNA expression…
- Conditions
- Ovarian Cancer, Ovarian Cyst Benign, Borderline Ovarian Cancer
- Trial name
- OVAmiARN (NCT05514028)
- Testing
- Salivary samples
- Where
- 21 sites in France, Switzerland and 1 more
- Volunteers
- 746 people
- Sponsor
- ZIWIG
Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan…
- Conditions
- Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors, Ovarian Germ Cell Tumor
- Trial name
- SUR-CAN (NCT05500391)
- Testing
- Oncological Follow-up
- Where
- 3 sites in France
- Volunteers
- 88 people
- Sponsor
- Centre Oscar Lambret
Borderline Ovarian Tumor
Experience in Borderline Ovarian Tumors
Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent an independent disease entity among epithelial ovarian cancers.
- Trial name
- NCT05791838
- Volunteers
- 86 people
- Sponsor
- University of Palermo
Low-grade Serous Ovarian Carcinoma, Recurrent Invasive Borderline Serous Ovarian Cancer
Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.
- Trial name
- MITO 22 (NCT02408536)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Naples
Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent).
- Conditions
- Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT00551070
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib
- Where
- 49 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Ovarian Tumors
Study Describing the Coverage, Cares and the Fertility of Patients of Less Than 45 Years With a Borderline Ovarian Tumor
Retrospective and prospective multi-center study Indication: Fertility-sparing surgery for patients with borderline ovarian tumor and fertility Objectives: Description of the characteristics of the patients of less than 45 years…
- Trial name
- OPTIBOT (NCT03690440)
- Where
- 11 sites in France
- Volunteers
- 176 people
- Sponsor
- Institut Curie
Adnexal Mass, Borderline Ovarian Epithelial Tumor
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
This pilot research trial studies folate receptor in diagnosing ovarian cancer using serum samples from patients with a newly diagnosed pelvic mass or previously diagnosed ovarian cancer.
- Conditions
- Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor
- Trial name
- NCT02520115
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Cancer, Borderline Ovarian Tumors
Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor
The aim of the study was to estimate the percentage and of Treg, Th17 and NKT in peripheral blood and the tissue of the epithelial ovarian tumor and relationship with blood serum level of HE4, CA125, as well as algorithm ROMA.
- Conditions
- Ovarian Cancer, Borderline Ovarian Tumors, Benign Ovarian Tumor, Unexplained Infertility
- Trial name
- NCT03779399
- Testing
- Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.
- Where
- Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Lublin
Epithelial Ovarian Cancer, Epithelial Ovarian Tumor of Borderline Malignancy
A Genomic Analysis of Evolution of Epithelia Ovarian Tumors
Epithelial ovarian carcinomatous and borderline components sometimes appeared in one patient. This study aims to analyze the genomic patterns of the carcinomatous and borderline components in the ovarian epithelial tissues.
- Conditions
- Epithelial Ovarian Cancer, Epithelial Ovarian Tumor of Borderline Malignancy, Driving Mutations, Progression-free Survival
- Trial name
- NCT03742388
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Lei Li
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma
- Trial name
- NCT00301756
- Testing
- Belinostat, Laboratory Biomarker Analysis
- Where
- 4 sites in Canada
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)